Georgia State University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4
Founded: Atlanta GA United States (1913)

Organization Overview

First Clinical Trial
2017
NCT03029819
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Department of Physical Therapy, Georgia State University | Georgia College and State University | Georgia State University

Active Ingredients

Drugs in Phase 4 Trials (1)

ocrelizumab (ocrevus) (1 trial)

Drugs in Phase 2 Trials (1)

cycloserine (seromycin) (1 trial)

Drugs in Phase 1 Trials (3)

gemcitabine (gemzar) (1 trial)

paclitaxel (taxol) (1 trial)

proagio (1 trial)

Drugs in Other Trials (1)

nicotine (nicorette) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anxiety Disorders (Phase 2)

Multiple Sclerosis (Phase 4)

Phobia, Social (Phase 2)

Sclerosis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 6